News

A study demonstrates that transcatheter aortic valve replacement is safe in patients with large aortic annuli. Heart failure complications remain an area of concern in this patient population.

Digest: Expands evidence for TAVR applicability in anatomically challenging cases with larger annular dimensions, though persistent heart failure risk may influence device selection and patient management strategies.

New data demonstrate superior outcomes for surgical aortic valve replacement (SAVR) compared to transcatheter aortic valve replacement (TAVR) in younger patients with aortic stenosis. The findings reinforce current clinical guidance favoring surgery over TAVR in younger, lower-risk patient populations.

Digest: These results support treatment allocation strategies and reinforce age-based selection criteria that impact procedural volumes and market share between TAVR platforms and surgical valve programs.

An AI-powered opportunistic screening tool is being developed to identify patients with undiagnosed aortic stenosis using existing imaging data. The technology aims to detect asymptomatic or unrecognized cases by analyzing routine medical scans that were performed for other clinical indications.

Digest: Early detection of aortic stenosis through opportunistic AI screening could identify intervention candidates before symptom onset, potentially improving outcomes and expanding the patient pool for TAVR and SAVR procedures.

Banner Health is partnering with physicians to expand cardiovascular procedures in ambulatory surgery centers. The initiative aims to shift appropriate heart procedures from hospital-based settings to lower-cost ASC environments.

Digest: ASC migration of structural heart procedures could impact reimbursement models and site-of-service strategies as health systems seek cost reduction while maintaining quality outcomes.

Ventripoint Diagnostics is expanding subscription-based access to its FDA-cleared VMS+ 4.0 platform, which uses AI and Knowledge Based Reconstruction technology to generate MRI-comparable 3D volumetric measurements of all four cardiac chambers from standard echocardiographic images. The company is implementing a Device-as-a-Service model targeting approximately 80% subscription-based adoption to reduce capital budget barriers for hospital implementation.

Digest: This AI-powered echocardiographic platform addresses a critical need for accurate right ventricular volumetric assessment without requiring MRI, with subscription pricing potentially lowering adoption barriers for structural heart programs evaluating patients for interventions.

ASCEND Cardiovascular and Epsilon Imaging announced a strategic partnership integrating ASCEND's enterprise structured reporting platform with Epsilon's EchoInsight Zero Footprint advanced echo analysis system featuring speckle-tracking strain imaging. The integrated solution uses AI-based view classification and bidirectional data exchange to automate strain measurement workflow, generating over 100 standardized measurements based on ASE chamber quantification guidelines without manual data entry.

Digest: Automated strain imaging integration addresses a key workflow barrier to routine use of global longitudinal strain for cardiotoxicity monitoring, heart failure assessment, and valvular disease management in structural heart programs.

Cardiologists have developed a novel anchoring technique to address challenging anatomical scenarios in transcatheter aortic valve replacement procedures. The technical innovation aims to improve procedural outcomes in complex TAVR cases where conventional deployment methods may be inadequate.

Digest: Procedural technique refinements for anatomically challenging cases may expand TAVR eligibility and reduce complications in high-risk subgroups such as those with hostile anatomy or severe calcification.

Emerging developments in cardiac CT include artificial intelligence-driven preventive imaging strategies and noncontrast imaging techniques. These advances aim to expand cardiac CT's clinical utility beyond current anatomical assessment capabilities.

Digest: Enhanced cardiac CT capabilities could improve preprocedural planning for structural heart interventions and risk stratification without contrast-related complications.

Incidental findings on pre-procedural CT scans demonstrate predictive value for mortality following transcatheter aortic valve replacement. The study suggests that non-cardiac imaging findings identified during routine TAVR planning may provide additional risk stratification capabilities.

Digest: Integration of incidental CT findings into TAVR risk assessment models could improve patient selection and prognostic accuracy beyond traditional cardiac risk scores.

The FDA has confirmed a new recall affecting accessories used with Abiomed's Impella percutaneous ventricular assist device system. Specific details regarding the affected accessory components, reason for recall, and adverse event data were not provided in the available article content.

Digest: Impella devices are widely used for hemodynamic support during high-risk PCI and cardiogenic shock management, making any recall of associated accessories clinically relevant for procedural safety and device availability.

An expert panel discussion examined current state and future directions of transcatheter aortic valve replacement technology and clinical practice. The panel format suggests coverage of evolving TAVR techniques, patient selection, and emerging challenges in the field.

Digest: Panel discussions at this stage of TAVR adoption typically address unresolved clinical questions around patient selection, durability, and expansion into lower-risk populations that guide practice patterns.

Economic analysis suggests early transcatheter aortic valve replacement in patients with asymptomatic severe aortic stenosis may be cost-effective compared to watchful waiting. The cost savings would accrue from preventing heart failure hospitalizations and complications associated with delayed intervention.

Digest: This health economics data could influence coverage decisions and clinical practice patterns by supporting intervention before symptom onset in severe AS patients.

New data from the PARTNER 3 trial demonstrate early clinical benefits of transcatheter aortic valve replacement (TAVR) compared to surgical aortic valve replacement (SAVR) in low-risk patients. The updated analysis reinforces TAVR's favorable early outcomes in this patient population.

Digest: These findings support expanding TAVR utilization in low-risk surgical candidates and may influence treatment algorithms and guideline recommendations for aortic stenosis management.

The U.S. Department of Justice charged 455 defendants, including 90 physicians and licensed healthcare professionals, with over $6.5 billion in alleged Medicare and Medicaid fraud in a 2026 national enforcement sweep. Healthcare law experts emphasize the need to distinguish between intentional fraud and honest billing mistakes resulting from complex regulatory requirements, as federal investigations continue with CMS deferring over $1 billion in Medicaid payments pending documentation review.

Digest: Heightened federal fraud enforcement and compliance scrutiny may impact structural heart practices through increased billing audits, reimbursement delays, and pressure to document medical necessity for high-cost procedures like TAVR and mitral interventions.

Abbott has initiated the Treat TR study, a post-market study enrolling approximately 1,000 patients across up to 100 sites in the U.S., Canada, and Europe to evaluate the safety and performance of the TriClip transcatheter edge-to-edge repair system for tricuspid regurgitation in real-world settings. Patients will be followed for five years, with a sub-study examining the system's potential to reverse cardiac remodeling.

Digest: This large-scale real-world evidence study will provide critical post-market performance data for TriClip TEER, informing adoption decisions and potentially expanding treatment paradigms for TR in clinical practice.

A biomarker enzyme ratio shows potential for predicting stroke and atrial fibrillation risk following transcatheter aortic valve replacement. The diagnostic tool could enable cardiologists to identify high-risk TAVR patients requiring enhanced monitoring or prophylactic intervention.

Digest: Risk stratification biomarkers for post-TAVR cerebrovascular and arrhythmic complications could improve patient selection, personalize antithrombotic strategies, and reduce adverse events in an expanding TAVR population.

Abbott is collecting real-world data on its TriClip transcatheter tricuspid valve repair system following FDA approval. The post-market data collection will provide insights into clinical outcomes and device performance outside of controlled trial settings.

Digest: Real-world evidence will be critical for understanding TriClip performance in broader patient populations and supporting clinical adoption in the emerging transcatheter tricuspid repair market.

HOPPR launched its fifth AI foundation model, the EF Chest CT Narrative Model, which processes 3D chest CT volumes to generate narrative reports across pulmonary, mediastinal, cardiac, upper abdominal, osseous, and soft tissue regions. The model was trained on a large proprietary U.S. dataset with deliberate overrepresentation of serious conditions including aortic injury, pulmonary embolism, rib fractures, and pneumothorax.

Digest: This AI model offers potential automated assessment of cardiac and aortic anatomy on chest CT, which could support preprocedural planning and screening for structural heart interventions, though clinical validation data were not provided.

ElectroWire Medical received FDA 510(k) clearance for the LightningWire Transseptal Puncture System, a novel electrosurgical guidewire designed to create atrial septal defects for left-sided cardiac procedures. The 0.032-inch diameter system features proprietary insulation enabling low-power transseptal puncture while providing stiffness comparable to 0.035-inch guidewires, with compatibility across existing electrosurgical generators and transseptal introducers.

Digest: This device addresses a critical access step for multiple structural heart procedures including TMVR, LAAO, and atrial fibrillation ablation, potentially improving procedural efficiency and reducing costs through platform-agnostic compatibility.

A new study examines failure to rescue rates following transcatheter aortic valve replacement (TAVR) procedures, comparing outcomes between high-volume and low-volume hospital centers. The analysis focuses on hospital-level differences in mortality following post-procedural complications.

Digest: Failure to rescue metrics may inform hospital volume-outcome relationships and quality benchmarking for TAVR programs, with implications for center credentialing and patient referral patterns.

A study found that less invasive anesthesia strategies during transcatheter aortic valve replacement are associated with improved clinical outcomes. The use of conscious sedation or local anesthesia instead of general anesthesia during TAVR procedures demonstrated a key benefit for patients.

Digest: Anesthesia strategy optimization represents a modifiable procedural factor that can improve TAVR outcomes and potentially reduce costs without requiring changes to valve technology or operator technique.

Medical societies are publicly responding to a CMS proposal regarding TAVR coverage as the agency approaches its final decision. The societies' positions indicate stakeholder engagement on potential changes to reimbursement or coverage criteria for transcatheter aortic valve replacement.

Digest: CMS coverage decisions directly impact patient access to TAVR and procedural volumes at structural heart programs, particularly if eligibility criteria or site-of-service requirements change.

An article discusses how artificial intelligence can assist heart teams in identifying appropriate patients for transcatheter aortic valve replacement. No specific AI platform, clinical data, or implementation details were provided in the available content.

Digest: AI-driven patient identification tools could improve TAVR referral patterns and reduce undertreatment of severe aortic stenosis, though clinical validation and implementation strategies remain unclear from this report.

At the Heart in Diabetes CME Conference, Dr. Katherine Tuttle presented an updated pillar-based treatment paradigm for chronic kidney disease, incorporating SGLT2 inhibitors, non-steroidal mineralocorticoid antagonists, GLP-1 receptor agonists, and RAS inhibitors, with endothelin type A receptor antagonists for nondiabetic CKD. Combination therapy in patients with type 2 diabetes and moderate albuminuria demonstrated significant risk reductions including 58% reduction in CKD progression (HR=0.42), 55% reduction in heart failure hospitalization (HR=0.45), and 35% reduction in major adverse cardiovascular events (HR=0.65) compared to conventional care.

Digest: Cardiometabolic optimization with these agents directly impacts structural heart patient selection, procedural risk stratification, and outcomes, as CKD and diabetes are critical comorbidities affecting valve intervention candidacy and post-procedural prognosis.

A cardiac surgeon performed the first robotic-assisted structural heart procedure of an unspecified type, representing a technical milestone in minimally invasive cardiac intervention. No clinical outcomes, procedural details, or patient data were provided in the available content.

Digest: Robotic platforms may expand minimally invasive options for structural heart procedures, though clinical efficacy and safety data are needed to assess impact on practice patterns.

Recent clinical data demonstrate long-term structural valve durability outcomes for transcatheter aortic valve replacement (TAVR) procedures. The findings provide cardiologists with evidence regarding hemodynamic performance and structural valve deterioration rates at extended follow-up intervals.

Digest: Long-term durability data are critical for informing TAVR patient selection, particularly in younger and lower-risk populations where valve longevity directly impacts lifetime management strategies.

A study identifies a simple biomarker that can predict which patients are at high risk for acute kidney injury following transcatheter aortic valve replacement. The biomarker enables cardiologists to stratify risk and potentially modify perioperative management in vulnerable TAVR patients.

Digest: Acute kidney injury is a significant complication after TAVR associated with increased morbidity and mortality, and preprocedural risk stratification could enable targeted renal protective strategies in high-risk patients.

Preliminary research presented at AHA Basic Cardiovascular Sciences 2026 identified a potential mechanistic link between Porphyromonas gingivalis bacteria from periodontal disease and calcific aortic valve stenosis (CAVS) through calcium deposition in aortic valve tissue. The lab study used mouse and human cardiac tissue to investigate the biological pathway connecting chronic gum infection to valve calcification.

Digest: This early-stage research suggests periodontal disease treatment could represent a novel preventive strategy for CAVS, a condition with no current pharmacologic therapies to prevent or slow progression prior to requiring valve replacement.

University of Maryland researchers developed an AI-powered clinical support tool that analyzes electronic health records to identify undiagnosed pulmonary hypertension by automatically extracting and predicting missing mean pulmonary artery pressure measurements from right heart catheterization reports. The system was tested on 17,292 catheterization reports from over 11,000 patients treated between 2016-2024, addressing the clinical challenge that mPAP is missing in 7-33% of cases depending on the dataset.

Digest: This tool addresses a diagnostic gap in pulmonary hypertension detection that affects appropriate patient selection and hemodynamic assessment for structural heart interventions, particularly in evaluating patients for tricuspid and mitral valve procedures where pulmonary pressures are critical eligibility criteria.

Medtronic has issued a recall of a heart valve delivery system due to an identified safety risk. Specific details regarding the affected device model, nature of the safety concern, patient impact, and scope of the recall were not provided in the available content.

Digest: Device recalls can impact procedural planning and inventory management for structural heart programs, and may signal potential adverse events requiring vigilance in patients who received the affected system.

Cardiologists report early favorable outcomes using a leaflet modification device to facilitate valve-in-valve TAVR procedures. The device appears to address challenges associated with coronary obstruction risk during ViV-TAVR interventions.

Digest: Leaflet modification techniques may expand treatment options for patients with failed surgical bioprostheses by reducing coronary obstruction risk, a major limitation of valve-in-valve TAVR.

The American Heart Association published a report from the Target: AS Registry examining quality metrics for evaluation, surveillance, and management of aortic stenosis patients. The registry aims to establish benchmarks and identify gaps in AS care delivery across participating centers.

Digest: This AHA registry provides standardized quality measures that can guide institutional protocols for AS patient management and inform appropriate timing for intervention referrals.

New follow-up data from the EARLY TAVR trial demonstrate continued clinical benefits of transcatheter aortic valve replacement in patients with asymptomatic severe aortic stenosis. The updated results reinforce the safety and efficacy of early intervention before symptom onset in this patient population.

Digest: These findings support expanding TAVR utilization to asymptomatic patients with severe AS, potentially shifting treatment paradigms and increasing the addressable patient population for structural heart programs.

Transcatheter aortic valve replacement using an Edwards Lifesciences valve system demonstrated encouraging outcomes in patients with severe aortic regurgitation. The data suggest TAVR may be a viable treatment option for this traditionally surgical patient population.

Digest: Severe AR has been a relative contraindication for TAVR due to anatomical challenges, and positive data could expand the treatment population and market for Edwards' valve technology.

A new meta-analysis examined sex-specific outcomes in patients undergoing transcatheter aortic valve replacement (TAVR) versus surgical aortic valve replacement (SAVR). The analysis revealed differential outcomes between male and female patients across the two treatment modalities.

Digest: Understanding sex-based differences in TAVR and SAVR outcomes can inform patient selection, procedural planning, and shared decision-making for aortic stenosis treatment.

This clinical reasoning exercise presents a case of slow regular rhythm developing after transcatheter aortic valve replacement (TAVR). The article appears to be an educational case discussion focusing on the differential diagnosis and management of bradycardia post-TAVR.

Digest: Conduction abnormalities requiring pacemaker implantation remain a significant complication of TAVR, affecting clinical outcomes and resource utilization in structural heart programs.

A high-intensity ultrasound technology designed to treat calcified valve leaflets has launched in Europe. No specific clinical data or device details were provided in the article content.

Digest: Novel leaflet modification technologies could expand treatment options for calcified valves, though clinical validation data are needed to assess utility in structural heart interventions.

CMS proposed significant policy changes affecting TAVR reimbursement and coverage, prompting responses from interventional cardiologists and cardiac surgeons. The clinical and financial implications of these proposed modifications are being evaluated by the structural heart community.

Digest: CMS reimbursement policy directly impacts TAVR program sustainability, patient access, and the economic viability of structural heart programs nationwide.

A family filed a $17 million lawsuit alleging that a heart valve was implanted upside down in a young girl during cardiac surgery. The complaint suggests surgical error resulting in improper valve orientation and subsequent patient harm.

Digest: Surgical valve orientation errors, while rare, represent a critical quality and safety concern that can lead to valvular dysfunction, reoperation, and medico-legal implications for cardiac surgery programs.

CMS has proposed expanding Medicare coverage for transcatheter aortic valve replacement (TAVR) to include asymptomatic patients with severe aortic stenosis. This represents a significant policy shift from current coverage criteria that require symptomatic presentation.

Digest: Expansion of Medicare coverage to asymptomatic severe AS patients could substantially increase the eligible TAVR population and accelerate treatment timing, potentially preventing symptom development and improving outcomes.

The SMART trial's 3-year results showed that self-expanding supra-annular TAVR valves (Evolut platform, Medtronic) demonstrated superior hemodynamics and less thrombosis compared to balloon-expandable valves (Sapien platform, Edwards Lifesciences) in patients with small aortic annuli (≤430 mm²). There was no difference in the composite clinical endpoint of mortality, disabling stroke, or heart failure rehospitalization between groups (self-expanding 25.4% vs balloon-expandable 22.6%; HR 1.13, 95% CI 0.83-1.53, P=0.44).

Digest: These extended follow-up data support the use of self-expanding supra-annular valves for improved hemodynamic performance in small annuli patients, particularly relevant for lower-risk and younger TAVR candidates where long-term valve function is critical.

A study demonstrates that redo transcatheter aortic valve replacement using balloon-expandable valves is associated with favorable clinical outcomes and key procedural improvements. The findings support the safety and efficacy of repeat TAVR procedures in patients with failed bioprosthetic valves.

Digest: As the TAVR population ages and device durability becomes critical, establishing safety profiles for redo TAVR with specific valve platforms helps guide treatment decisions for structural valve degeneration.

A European registry of over 11,000 TAVR patients found that 4% died between 30 days and one year post-procedure despite uncomplicated courses, with 3.3% from non-cardiovascular causes. Independent predictors of delayed mortality included atrial fibrillation, COPD, severe chronic kidney disease, and reduced LVEF.

Digest: These findings emphasize the need for comprehensive multidisciplinary patient assessment beyond cardiac evaluation to identify patients at risk for futile TAVR interventions, particularly focusing on pulmonary and renal comorbidities that drive non-cardiovascular mortality.

Cardiologists and patient family members have raised concerns about quality of care related to TAVR procedures at an unspecified rural hospital. Details regarding specific adverse events, procedural volumes, or outcomes data were not provided in the available content.

Digest: Quality concerns at low-volume rural TAVR centers may prompt scrutiny of procedural volume requirements and certification standards for transcatheter valve programs.

Badano et al published a letter to the editor commenting on a previously published article examining exercise right ventricular-pulmonary arterial coupling as a prognostic marker in primary mitral regurgitation. This correspondence addresses methodological or interpretive aspects of the original research on RV-PA coupling assessment during exercise in mitral regurgitation patients.

Digest: Exercise RV-PA coupling may inform patient selection and timing decisions for transcatheter or surgical mitral valve interventions in primary mitral regurgitation.

This is a correspondence response by Moura-Ferreira et al addressing a previously published article on the prognostic value of exercise right ventricular-pulmonary arterial coupling in primary mitral regurgitation. The response provides commentary or additional perspective on the original research findings regarding RV-PA coupling assessment during exercise in MR patients.

Digest: Exercise RV-PA coupling assessment may refine risk stratification and surgical timing decisions in primary mitral regurgitation patients, particularly those with preserved left ventricular function.

A new guideline has been published to standardize echocardiographic guidance protocols for mitral transcatheter edge-to-edge repair (M-TEER) procedures. The guideline aims to harmonize imaging practices across operators and centers performing M-TEER interventions.

Digest: Standardized echo guidance protocols can improve procedural outcomes, reduce variability in M-TEER technique, and establish benchmarks for quality assurance in this growing mitral valve intervention field.

The FDA has granted clearance for the first surgical valve specifically designed for tricuspid valve replacement. This represents the first dedicated tricuspid prosthesis approved for surgical implantation, addressing a previously unmet need in tricuspid valve disease management.

Digest: This approval provides cardiac surgeons with a purpose-built solution for tricuspid valve replacement, potentially improving outcomes compared to off-label use of mitral or aortic prostheses in the tricuspid position.

The Society of Cardiovascular Computed Tomography (SCCT) 2026 annual meeting featured presentations focused on plaque imaging techniques, artificial intelligence applications, and structural heart disease. The conference highlighted advances in CT-based cardiac imaging modalities relevant to structural interventions.

Digest: SCCT conference coverage demonstrates the growing integration of advanced CT imaging and AI tools in pre-procedural planning and risk stratification for structural heart interventions.

Article discusses risk assessment strategies for patients who previously underwent TAVR and subsequently require non-cardiac or cardiac surgical procedures. Clinical considerations include evaluating perioperative risk in the context of existing bioprosthetic valves and potential complications.

Digest: As TAVR expands to younger, lower-risk populations, understanding how to manage these patients when they need subsequent surgical interventions becomes increasingly important for procedural planning and risk stratification.